[go: up one dir, main page]

AR011190A1 - Empleo de derivados de pirimidina para la preparacion de un medicamento para la profilaxis de la formacion de tumores solos o en combinacion con otroscompuestos terapeuticos - Google Patents

Empleo de derivados de pirimidina para la preparacion de un medicamento para la profilaxis de la formacion de tumores solos o en combinacion con otroscompuestos terapeuticos

Info

Publication number
AR011190A1
AR011190A1 ARP980101097A ARP980101097A AR011190A1 AR 011190 A1 AR011190 A1 AR 011190A1 AR P980101097 A ARP980101097 A AR P980101097A AR P980101097 A ARP980101097 A AR P980101097A AR 011190 A1 AR011190 A1 AR 011190A1
Authority
AR
Argentina
Prior art keywords
alkyl
heteroaryl
aryl
alkoxy
trifluoromethyl
Prior art date
Application number
ARP980101097A
Other languages
English (en)
Original Assignee
Hoechst Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Ag filed Critical Hoechst Ag
Publication of AR011190A1 publication Critical patent/AR011190A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Empleo de un derivado de pirimidina de la formula (I) en donde R1 significa hidrogeno, halogeno, ciano, nitro, trifluorometilo, amino, alquilo (C1-C6),hidroxialquilo (C1-C6), alcoxi (C1-C6), arilo (C6-C12), alcoxi (C1-C6)- carbonilalquilo(C1 -C6), alquil (C1-C6)-S-alquilo (C1-C6), alquil (C1-C6)SO-alquilo (C1-C6), alquil (C1-C6)-SO2-alquilo (C1-C6), dihidroxi-alquilo (C1-C6), arilo, heteroarilo, heteroaril-alquilo (C1-C6) aril-alquilo (C1-C6) alcoxi(C1-C6)-carbonilarilo, aril-alcoxi(C1- C6) o heteroaril-alquiloxi (C1-C6), heteroarilo significa piridilo, furilo, tetrahidrofurilo, tienilo, imidazolilo,pirazolilo, triazolilo, tiazolilo, oxazolilo, benozotiazolilo; pudiendo arilo y heteroarilo, independientemente uno de otro,estar sustituidos con uno o variossustituyentes elegidos del grupo cloro, bromo, alquilo (C1-C6), alcoxi (C1-C6), -S-alquilo (C1-C6), -SO-alquilo (C1-C6), -SO2- alquilo (C1-C6), hidroxialquilo(C1-C6), trifluorometilo, o R1 significa (II), en dondela líne a de trazos discontínuos representa un doble enlace opcional; W, Q, Z significaindependientemente uno de otro, H, alquilo (C1-C6), trifluorometilo, fenilo, furilo, triazolilo, tiazolilo, tienilo, independientemente uno deotro,sustituidos de una a tres veces con alquilo (C1-C6), alcoxi (C1-C6), trifluorometilo, hidroxi o R1 significa -(C=O)-R6, R6 significa H, alquilo(C1-C6), arilo, heteroarilo, heteroarilo significa piridilo, furilo,tetrahidrofurilo, tienilo, imid azolilo, pirazolilo, triazolilo, tiazolilo,oxazolilo, benzotiazolilo<<, pudiendo estar arilo y heteroarilo, independiente uno del otro, sustituidos con uno a tres sustituyentes elegidos del grupocloro, bromo, nitro,trifluorometilo, alcoxi (C1-C6), -SO2-alquilo (C1-C6) o R1 significa (III), R7 significa arilo, heteroarilo, heteroarilo significa
ARP980101097A 1997-03-13 1998-03-11 Empleo de derivados de pirimidina para la preparacion de un medicamento para la profilaxis de la formacion de tumores solos o en combinacion con otroscompuestos terapeuticos AR011190A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19710435A DE19710435A1 (de) 1997-03-13 1997-03-13 Verwendung von Pyrimidinderivaten zur Prävention von Krebs allein oder in Kombination mit anderen therapeutischen Maßnahmen

Publications (1)

Publication Number Publication Date
AR011190A1 true AR011190A1 (es) 2000-08-02

Family

ID=7823277

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP980101097A AR011190A1 (es) 1997-03-13 1998-03-11 Empleo de derivados de pirimidina para la preparacion de un medicamento para la profilaxis de la formacion de tumores solos o en combinacion con otroscompuestos terapeuticos

Country Status (19)

Country Link
US (1) US6156755A (es)
EP (1) EP0864327B1 (es)
JP (1) JPH10279482A (es)
KR (1) KR19980080148A (es)
CN (1) CN1193513A (es)
AR (1) AR011190A1 (es)
AT (1) ATE227129T1 (es)
AU (1) AU726089B2 (es)
BR (1) BR9800884A (es)
CA (1) CA2231765A1 (es)
CZ (1) CZ74698A3 (es)
DE (2) DE19710435A1 (es)
DK (1) DK0864327T3 (es)
ES (1) ES2182161T3 (es)
HU (1) HUP9800535A1 (es)
PL (1) PL325327A1 (es)
PT (1) PT864327E (es)
RU (1) RU2209629C2 (es)
TR (1) TR199800436A3 (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002523497A (ja) 1998-08-29 2002-07-30 アストラゼネカ・アクチエボラーグ ピリミジン化合物
JP2002523498A (ja) 1998-08-29 2002-07-30 アストラゼネカ・アクチエボラーグ ピリミジン化合物
GB9828511D0 (en) 1998-12-24 1999-02-17 Zeneca Ltd Chemical compounds
GB9905075D0 (en) 1999-03-06 1999-04-28 Zeneca Ltd Chemical compounds
GB9907658D0 (en) 1999-04-06 1999-05-26 Zeneca Ltd Chemical compounds
GB9919778D0 (en) 1999-08-21 1999-10-27 Zeneca Ltd Chemical compounds
GB0004886D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004888D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004890D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004887D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0007371D0 (en) 2000-03-28 2000-05-17 Astrazeneca Uk Ltd Chemical compounds
GB0016877D0 (en) 2000-07-11 2000-08-30 Astrazeneca Ab Chemical compounds
GB0021726D0 (en) 2000-09-05 2000-10-18 Astrazeneca Ab Chemical compounds
US6716851B2 (en) 2000-12-12 2004-04-06 Cytovia, Inc. Substituted 2-aryl-4-arylaminopyrimidines and analogs as activators or caspases and inducers of apoptosis and the use thereof
MXPA03005609A (es) * 2000-12-21 2003-10-06 Vertex Pharma Compuestos de pirazol utiles como inhibidores de la proteina cinasa.
GB0103926D0 (en) 2001-02-17 2001-04-04 Astrazeneca Ab Chemical compounds
GB0113041D0 (en) 2001-05-30 2001-07-18 Astrazeneca Ab Chemical compounds
US6825198B2 (en) * 2001-06-21 2004-11-30 Pfizer Inc 5-HT receptor ligands and uses thereof
TWI330183B (es) * 2001-10-22 2010-09-11 Eisai R&D Man Co Ltd
GB0205688D0 (en) 2002-03-09 2002-04-24 Astrazeneca Ab Chemical compounds
US7442697B2 (en) 2002-03-09 2008-10-28 Astrazeneca Ab 4-imidazolyl substituted pyrimidine derivatives with CDK inhibitory activity
GB0205693D0 (en) 2002-03-09 2002-04-24 Astrazeneca Ab Chemical compounds
GB0205690D0 (en) 2002-03-09 2002-04-24 Astrazeneca Ab Chemical compounds
RS51752B (sr) * 2002-07-29 2011-12-31 Rigel Pharmaceuticals Metode tretiranja i prevencije autoimunih oboljenja jedinjenjima 2,4-pirimidindiamina
RU2376992C2 (ru) * 2002-07-29 2009-12-27 Райджел Фармасьютикалз, Инк. Способы лечения или профилактики аутоиммунных заболеваний с помощью соединений 2,4-пиримидиндиамина
GB0311274D0 (en) 2003-05-16 2003-06-18 Astrazeneca Ab Chemical compounds
GB0311276D0 (en) 2003-05-16 2003-06-18 Astrazeneca Ab Chemical compounds
GB0323137D0 (en) * 2003-10-03 2003-11-05 Chang Lisa C W 2,4,6- Trisubstituted pyrimidines and their different uses
BRPI0417478A (pt) * 2003-12-15 2007-05-08 Almirall Prodesfarma Ag 2,6-bis-heteroaril-4-aminopirimidinas como antagonistas de receptor de adenosina
TW200528101A (en) 2004-02-03 2005-09-01 Astrazeneca Ab Chemical compounds
WO2006110884A2 (en) * 2005-04-11 2006-10-19 Neurocrine Biosciences, Inc. 2, 6-di (hetero) aryl -4-amido-pyrimidines as adenosine receptor antagonists
US20060293343A1 (en) * 2005-05-18 2006-12-28 Asahi Kasei Pharma Corporation Pyrimidine derivatives
US7745428B2 (en) 2005-09-30 2010-06-29 Astrazeneca Ab Imidazo[1,2-A]pyridine having anti-cell-proliferation activity
WO2008070661A1 (en) * 2006-12-04 2008-06-12 Neurocrine Biosciences, Inc. Substituted pyrimidines as adenosine receptor antagonists
US20100249084A1 (en) * 2007-03-21 2010-09-30 Youngsheng Chen Substituted pyrimidines as adenosine receptor antagonists

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB884772A (en) * 1958-01-16 1961-12-20 Merck & Co Inc 2-alkoxy-4-amino pyrimidines
DE3905364A1 (de) * 1989-02-22 1990-08-23 Hoechst Ag Substituierte pyrimidin-derivate, verfahren zu ihrer herstellung und ihre verwendung als tool
DE4025387A1 (de) * 1990-08-10 1992-02-13 Hoechst Ag Substituierte pyrimidin-derivate, verfahren zu ihrer herstellung und ihre verwendung als reagenzien
KR950703539A (ko) * 1992-09-28 1995-09-20 알렌 제이. 스피겔 당뇨병 합병증 치료용 치환된 피리미딘(substituted pyrimidines for control or diabetic complications)

Also Published As

Publication number Publication date
AU5835098A (en) 1998-09-17
HU9800535D0 (en) 1998-04-28
PL325327A1 (en) 1998-09-14
RU2209629C2 (ru) 2003-08-10
TR199800436A2 (xx) 1998-10-21
AU726089B2 (en) 2000-11-02
BR9800884A (pt) 1999-12-07
US6156755A (en) 2000-12-05
KR19980080148A (ko) 1998-11-25
DE19710435A1 (de) 1998-09-17
EP0864327A1 (de) 1998-09-16
ATE227129T1 (de) 2002-11-15
EP0864327B1 (de) 2002-11-06
TR199800436A3 (tr) 1998-10-21
DE59806139D1 (de) 2002-12-12
CA2231765A1 (en) 1998-09-13
PT864327E (pt) 2003-03-31
JPH10279482A (ja) 1998-10-20
ES2182161T3 (es) 2003-03-01
DK0864327T3 (da) 2003-02-17
CN1193513A (zh) 1998-09-23
CZ74698A3 (cs) 1998-09-16
HUP9800535A1 (hu) 2000-11-28

Similar Documents

Publication Publication Date Title
AR011190A1 (es) Empleo de derivados de pirimidina para la preparacion de un medicamento para la profilaxis de la formacion de tumores solos o en combinacion con otroscompuestos terapeuticos
AR041262A1 (es) Metodos para tratar los trastornos de ojo seco
TR200102001T2 (tr) P38 kinaz inhibitörleri olarak sübstitüe edilmiş pirazoller
CO5540306A2 (es) Derivados de n-aroil-amina ciclica como antagonistas del receptor de orexina
NO20062130L (no) 4-(pyrazol-3-ylamino)pyrimidinderivater for anvendelse i behandling av kreft
NO20034632D0 (no) 2-iminopyrrolidin-derivater
AR006906A1 (es) Derivados de indazol sustituidos, composiciones farmaceuticas que los contienen, uso de los mismos e intermediarios de sintesis
HUP0400540A2 (hu) 2-Pirazolin-5-on-származékok, alkalmazásuk és ezeket tartalmazó gyógyászati készítmények
SE0001207D0 (sv) Novel compounds
JO2274B1 (en) Derivatives of 1-renesulfinyl-2-aryl-pyrrolidine and piperidine
RU2009122505A (ru) Способы сохранения функции почек с использованием ингибиторов ксантин оксидоредуктазы
MXPA03010445A (es) Derivados de 4(fenil-piperazinil-metil) benzamida y su uso para tratamiento del dolor, ansiedad o trastornos gastrointestinales.
LV5803B4 (lv) Heterocikliskie atvasinajumi to iegusanas panemiens un to terapeitiska izmantosana par PAF-antagonistu
DE602005023544D1 (de) Angiogeneseinhibitoren
NO20022232D0 (no) Imidazolforbindelser for anvendelse som inhibitorer for fosfodiesterase VII
SE0101765D0 (sv) Novel compounds
DE60320849D1 (de) Anti-angiogenetische arzneimittel
SE0101766D0 (sv) Novel compounds
SE0001208D0 (sv) Novel compounds
SE0001209D0 (sv) Novel compounds
ATE337320T1 (de) Indolderivate als pde5-inhibitoren
NO20022123D0 (no) Osoksazolderivater for anvendelse som inhibitorer for fosfodiesterase VII
NZ309499A (en) Styryl benzimidazole derivatives useful as inhibitors of smooth muscle cell proliferation
DK440486A (da) Antipsykotiske gamma-carboliner
HRP20040617B1 (hr) Derivati 5-(piridin-3-il)-1-azabiciklo[3.2.1]oktana, njihova priprava i primjena u nekim terapijskim sredstvima

Legal Events

Date Code Title Description
FB Suspension of granting procedure